Further studies are needed to determine if SIK inhibitors increase 1,25-vitamin D levels of other CKD models with interstitial fibrosis and to assess the effect of long-term SIK inhibitor treatment on clinically relevant CKD-MBD endpoints, such as vascular calcification and renal osteodystrophy. This evidence concerns the gene SIK1 and chronic kidney disease.